Plasma Phospho-tau217: More Evidence of Potential as a Biomarker for Alzheimer Disease

Longitudinal changes in plasma p-tau217 levels are more pronounced in those with Alzheimer disease.

Plasma tau phosphorylated at threonine 217 (p-tau217) is emerging as a useful Alzheimer disease (AD) biomarker (NEJM JW Neurol Nov 2020 and JAMA 2020; 324:772). Researchers analyzed the trajectory of plasma p-tau217 levels in 150 cognitively unimpaired adults and 100 adults with mild cognitive impairment (MCI), with biennial measurements for up to 6 years. Longitudinal outcomes also included conversion from MCI to AD dementia in those who had positive amyloid-beta (Aβ+) levels versus negative amyloid-beta (Aβ−) levels in the cerebrospinal fluid (CSF), cognitive performance, and cerebral atrophy on MRI. Plasma neurofilament light (NfL) chain levels were also obtained.

Among all participants (mean age, about 70 years; about 25%–60% female), 48…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Plasma Phospho-tau217: More Evidence of Potential as a Biomarker for Alzheimer Disease

Topics

Reviewing Author